Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month*
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Business Wire
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), the leading health and wellness platform, today announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Wegovy®**. This needle-free treatment joins a full suite of weight loss solutions designed to meet the specific needs and preferences of individual customers.This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260205680502/en/By leveraging nearly a decade of infrastructure investment to drive radical affordability, Hims & Hers is making personalized care more accessible than ever. Starting today, eligible customers can access treatment plans that include Compounded Semaglutide Pills at a special introductory offer starting at just $49 for the first month*.The new Compounded Semaglutide Pill is formulated to protect the active ingredient during
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- FDA to restrict GLP-1 ingredients used in non-approved compounded drugs [CNBC]CNBC
- FDA to restrict GLP-1 ingredients used in non-approved compounded drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Eli Lilly, Novo down as Hims to offer cheaper weight-loss pill [Seeking Alpha]Seeking Alpha
- Hims and Hers Health's compounded Wegovy pill offering fuels market jitters [Yahoo! Finance]Yahoo! Finance
- Instant View: Hims and Hers Health's compounded Wegovy pill offering fuels market jitters [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 11/3/25 - Miss
HIMS
Sec Filings
- 2/4/26 - Form 4
- 1/21/26 - Form 4
- 1/20/26 - Form 144
- HIMS's page on the SEC website